Morgan Stanley
AST.WS

Morgan Stanley’s Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) AST.WS Stock Holding History

Morgan Stanley’s Portfolio AST.WS Stock Details AST.WS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,345
Closed -$1K – 6829
2017
Q2 		$1K Sell
1,345
-305
-18% -$138 ﹤0.01% 6566
2017
Q1 		$0 Buy
1,650
+304
+23% +$112 ﹤0.01% 6777
2016
Q4 		$1K Sell
1,346
-4,329
-76% -$2.32K ﹤0.01% 6505
2016
Q3 		$3K Sell
5,675
-223
-4% -$61 ﹤0.01% 6352
2016
Q2 		$1K Buy
+5,898
New +$3.07K ﹤0.01% 6486

Morgan Stanley's AST.WS Position: Q3 2017 in Review

Morgan Stanley sold out of Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) (AST.WS) in Q3 2017, closing a stake of 1,345 shares — an estimated $1K sold.

Morgan Stanley first reported a position in AST.WS in Q2 2016 and held it in 5 quarters. The position peaked at $3K in Q3 2016. 3 funds tracked by Wall St. Rank hold AST.WS as of Q3 2017.

  • Morgan Stanley reported no remaining Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) position as of Q3 2017 after selling out during the quarter.
  • Morgan Stanley sold 1,345 Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) shares in Q3 2017, an estimated $1K.
  • Morgan Stanley first reported a position in Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) in Q2 2016 and held it in 5 quarters.
  • Morgan Stanley's Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) position peaked at $3K in Q3 2016.
  • 3 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017) as of Q3 2017.

Based on Morgan Stanley's 13F filing for Q3 2017, filed 14 Nov 2017.